Researchers have received a $2.4m grant from the U.S. Department of Defense Breast Cancer Research Program to validate a new blood test for the early detection of breast cancer.
They are evaluating Syantra DX Breast Cancer – an experimental diagnostic test that detects specific biomarkers in blood associated with breast cancer.
The test uses an artificial intelligence algorithm to determine whether a patient is positive for cancer as soon as detectable by mammogram, or possibly earlier, and before symptoms arise.
“This new liquid biopsy, or blood test, has the potential to detect breast cancer at a very early stage. Early diagnosis means treatment can start sooner when it is most effective, saving lives,” said the study’s principal investigator Dr Massimo Cristofanilli, Professor of Medicine at Weill Cornell Medicine.
The team will evaluate the performance of the Syantra DX Breast Cancer test in women aged 30 to 75 who have an elevated risk of developing breast cancer, including those with dense breast tissue, abnormal mammograms, genetic predisposition, or suspicious breast symptoms.
Participants will have their blood drawn for the liquid biopsy and also complete standard-of-care screening with mammography or any other physician-recommended procedures such as MRI or ultrasound, which can help screen dense breast tissue.
The primary objective is to measure the Syantra DX Breast Cancer test’s specificity and sensitivity. A positive test result will always require follow-up assessment with a pathologist who will use biopsy tissue to confirm a diagnosis.
In addition, the researchers hope the test can be used worldwide in underserved populations or where access to standard imaging equipment isn’t readily available.
Image credit | Syantra-inc
